Non-Current Liabilities
Other Non-Current Liabilities
Vertex Pharmaceuticals Other Non-Current Liabilities decreased by 1.1% to $1.26B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 31.9%, from $951.9M to $1.26B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 63.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
Significant increases may indicate future cash outflows or deferred tax impacts that could affect long-term earnings.
Detailed definition
This category captures long-term obligations that do not fit into standard classifications like long-term debt or pensio...
Peer comparison
Standard across most large companies; often contains unique, company-specific long-term accruals.
Metric ID:
other_non_current_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $107.69M | $108.47M | $303.3M | $117.4M | $115.4M | $115.7M | $685.8M | $726.5M | $759.3M | $869.3M | $877.7M | $853.6M | $876.8M | $933.3M | $1.01B | $951.9M | $1.2B | $1.23B | $1.27B | $1.26B |
| QoQ Change | — | +0.7% | +179.6% | -61.3% | -1.7% | +0.3% | +492.7% | +5.9% | +4.5% | +14.5% | +1.0% | -2.7% | +2.7% | +6.4% | +8.7% | -6.2% | +25.6% | +3.2% | +2.9% | -1.1% |
| YoY Change | — | — | — | — | +7.2% | +6.7% | +126.1% | +518.8% | +558.0% | +651.3% | +28.0% | +17.5% | +15.5% | +7.4% | +15.6% | +11.5% | +36.3% | +32.2% | +25.1% | +31.9% |
Range$107.69M – $1.27B
CAGR+67.7%
Avg YoY Growth+130.6%
Median YoY Growth+26.6%
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other non-current liabilities?
- Vertex Pharmaceuticals (VRTX) reported other non-current liabilities of $1.26B in Q1 2026.
- How has Vertex Pharmaceuticals's other non-current liabilities changed year-over-year?
- Vertex Pharmaceuticals's other non-current liabilities increased by 31.9% year-over-year, from $951.9M to $1.26B.
- What is the long-term trend for Vertex Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's other non-current liabilities has grown at a 63.6% compound annual growth rate (CAGR), from $108.4M to $1.27B.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts or obligations that do not fall into standard categories.